A first-in-human phase 1 study of proxalutamide (GT0918), a dual MOA androgen receptor blocker in patients with advanced CRPC.
- Resource Type
- Journal
- Source
JOURNAL OF CLINICAL ONCOLOGY ; MAY 20 2017, 35 5p. Supplement: 15- Subject
- Language
- English
- ISSN
- 15277755